Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Breast 3Gastrointestinal 2Thoracic 1Gynecologic 1

Conditions

Prostatic Neoplasms 683Carcinoma, Renal Cell 225Urinary Bladder Neoplasms 195Carcinoma, Transitional Cell 111Breast Neoplasms 96Kidney Neoplasms 89Carcinoma, Non-Small-Cell Lung 82Neoplasms 81Melanoma 78Ovarian Neoplasms 77Colorectal Neoplasms 68Neoplasm Metastasis 66Non-Muscle Invasive Bladder Neoplasms 56Lung Neoplasms 53Pancreatic Neoplasms 46Sarcoma 45Stomach Neoplasms 42Endometrial Neoplasms 41Uterine Cervical Neoplasms 39Wilms Tumor 33Adenocarcinoma 33Esophageal Neoplasms 31Carcinoma, Hepatocellular 31Squamous Cell Carcinoma of Head and Neck 30Triple Negative Breast Neoplasms 29Head and Neck Neoplasms 27Testicular Neoplasms 24Metastatic Castration-resistant Prostate Cancer 24Neuroblastoma 23Colonic Neoplasms 23

Interventions

pembrolizumab 2enfortumab vedotin 2Single Person 1Exercise 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × Genitourinary × 90 days × Clear all
NCT07629700 2026-06-05

ENDEAVOR

University of Florence

Phase NA Not yet recruiting
40 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Generate Biomedicines

Phase 1 Recruiting
37 enrolled
Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT07548476 2026-05-04

ACE

Dana-Farber Cancer Institute

Phase NA Not yet recruiting
50 enrolled
Genitourinary

Urinary Bladder Neoplasms, Peripheral Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡